Selective α2C Antagonists for Diabetic Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular disorders and diabetic complications, such as diabetic foot ulcers, lack effective and selective adrenoreceptor α2C receptor antagonists to modulate the activated adrenergic system, leading to inadequate management of conditions like hypertension, heart failure, and impaired wound healing.
Innovation Solution
Development of novel substituted piperidinyltetrahydroquinolines that act as selective adrenoreceptor α2C receptor antagonists, capable of vasorelaxation, inhibiting platelet aggregation, and improving blood flow, thereby addressing cardiovascular and diabetic-related pathophysiological conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cardiovascular disorders and diabetic complications are used, then general management of these conditions is maintained, but selective modulation of the activated adrenergic system is insufficient, leading to inadequate management of hypertension, heart failure, and impaired wound healing
Solution Approach 1:
The invention segments the adrenergic receptor system by developing compounds that selectively target the α2C receptor subtype. The substituted piperidinyltetrahydroquinoline compounds are designed to specifically bind to and antagonize α2C adrenergic receptors, thereby segmenting the broad adrenergic system into selectively modulatable components. This allows for precise pharmacological intervention in specific pathophysiological conditions without affecting other adrenergic receptor subtypes.
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular structures (substituted piperidinyltetrahydroquinolines) that possess tailored pharmacological properties for selective α2C receptor antagonism. The chemical structure is optimized to confer selectivity for the α2C subtype, enabling localized and specific modulation of adrenergic activity in target tissues such as vascular smooth muscle and platelets, thereby improving treatment effectiveness for cardiovascular and diabetic complications.
2Reliability
If selective adrenoreceptor α2C receptor antagonists are developed, then effective management of cardiovascular disorders and diabetic complications is achieved, but the complexity of drug development and clinical validation increases
Solution Approach 1:
The invention employs preliminary action by conducting comprehensive in vitro and in vivo characterization of the substituted piperidinyltetrahowquinoline compounds during the development phase. Extensive preclinical studies including binding assays, functional experiments, and pharmacokinetic profiling are performed beforehand to establish the selectivity and efficacy of the compounds. This preliminary characterization provides a robust foundation for clinical translation, thereby managing the overall development complexity while ensuring reliable treatment effectiveness.
3Reliability
If compounds are designed for high selectivity of α2C receptor antagonism, then improved peripheral blood flow and wound healing are achieved, but the requirements for manufacturing precision and purity increase
Solution Approach 1:
The invention applies parameter changes by optimizing the chemical structure parameters of the substituted piperidinyltetrahowquinoline compounds to achieve high selectivity for α2C receptors. Specific substitutions on the piperidinyl and tetrahowquinoline rings are tailored to enhance binding affinity and selectivity. These structural parameter optimizations inherently establish clear specifications for manufacturing purity and quality control, as the selective pharmacological activity depends on precise molecular characteristics.
Data Source
AI summary
The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.